nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—ABCB1—colon cancer	0.283	1	CbGaD
Tacrolimus—CYP3A7-CYP3A51P—Irinotecan—colon cancer	0.0406	0.109	CbGbCtD
Tacrolimus—CYP3A7—Irinotecan—colon cancer	0.0406	0.109	CbGbCtD
Tacrolimus—ALB—Irinotecan—colon cancer	0.0379	0.101	CbGbCtD
Tacrolimus—ALB—Fluorouracil—colon cancer	0.0363	0.0974	CbGbCtD
Tacrolimus—CYP3A7—Vincristine—colon cancer	0.0355	0.095	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Vincristine—colon cancer	0.0355	0.095	CbGbCtD
Tacrolimus—CYP3A5—Irinotecan—colon cancer	0.0304	0.0816	CbGbCtD
Tacrolimus—CYP3A5—Vincristine—colon cancer	0.0266	0.0713	CbGbCtD
Tacrolimus—ALB—Methotrexate—colon cancer	0.02	0.0537	CbGbCtD
Tacrolimus—ABCB1—Irinotecan—colon cancer	0.0198	0.0531	CbGbCtD
Tacrolimus—ABCB1—Vincristine—colon cancer	0.0173	0.0464	CbGbCtD
Tacrolimus—CYP3A4—Irinotecan—colon cancer	0.0119	0.0318	CbGbCtD
Tacrolimus—ABCB1—Methotrexate—colon cancer	0.0105	0.0281	CbGbCtD
Tacrolimus—CYP3A4—Vincristine—colon cancer	0.0104	0.0278	CbGbCtD
Tacrolimus—ORM1—bile—colon cancer	0.00771	0.114	CbGeAlD
Tacrolimus—MTOR—blood vessel—colon cancer	0.00323	0.0478	CbGeAlD
Tacrolimus—ABCA5—bone marrow—colon cancer	0.00221	0.0327	CbGeAlD
Tacrolimus—ORM1—gall bladder—colon cancer	0.00214	0.0317	CbGeAlD
Tacrolimus—ABCA5—vagina—colon cancer	0.00212	0.0314	CbGeAlD
Tacrolimus—PPP3CA—smooth muscle tissue—colon cancer	0.00205	0.0304	CbGeAlD
Tacrolimus—PPP3CA—renal system—colon cancer	0.00197	0.0292	CbGeAlD
Tacrolimus—MTOR—embryo—colon cancer	0.00193	0.0285	CbGeAlD
Tacrolimus—ALB—gall bladder—colon cancer	0.00188	0.0278	CbGeAlD
Tacrolimus—ABCA5—liver—colon cancer	0.00179	0.0265	CbGeAlD
Tacrolimus—PPP3CA—lymphoid tissue—colon cancer	0.00164	0.0243	CbGeAlD
Tacrolimus—PPP3CA—digestive system—colon cancer	0.00162	0.024	CbGeAlD
Tacrolimus—MTOR—epithelium—colon cancer	0.00157	0.0233	CbGeAlD
Tacrolimus—MTOR—smooth muscle tissue—colon cancer	0.00151	0.0224	CbGeAlD
Tacrolimus—PPP3CA—bone marrow—colon cancer	0.00149	0.0221	CbGeAlD
Tacrolimus—MTOR—renal system—colon cancer	0.00146	0.0216	CbGeAlD
Tacrolimus—PPP3CA—vagina—colon cancer	0.00143	0.0212	CbGeAlD
Tacrolimus—FKBP1A—epithelium—colon cancer	0.00141	0.0209	CbGeAlD
Tacrolimus—ABCA5—lymph node—colon cancer	0.00137	0.0203	CbGeAlD
Tacrolimus—FKBP1A—smooth muscle tissue—colon cancer	0.00136	0.0202	CbGeAlD
Tacrolimus—FKBP1A—renal system—colon cancer	0.00131	0.0194	CbGeAlD
Tacrolimus—MTOR—lymphoid tissue—colon cancer	0.00121	0.0179	CbGeAlD
Tacrolimus—PPP3CA—liver—colon cancer	0.00121	0.0179	CbGeAlD
Tacrolimus—MTOR—digestive system—colon cancer	0.0012	0.0177	CbGeAlD
Tacrolimus—MTOR—bone marrow—colon cancer	0.0011	0.0163	CbGeAlD
Tacrolimus—FKBP1A—lymphoid tissue—colon cancer	0.00109	0.0161	CbGeAlD
Tacrolimus—FKBP1A—digestive system—colon cancer	0.00108	0.0159	CbGeAlD
Tacrolimus—MTOR—vagina—colon cancer	0.00106	0.0156	CbGeAlD
Tacrolimus—FKBP1A—bone marrow—colon cancer	0.000991	0.0147	CbGeAlD
Tacrolimus—CYP3A7—liver—colon cancer	0.000991	0.0147	CbGeAlD
Tacrolimus—FKBP1A—vagina—colon cancer	0.00095	0.0141	CbGeAlD
Tacrolimus—PPP3CA—lymph node—colon cancer	0.000925	0.0137	CbGeAlD
Tacrolimus—MTOR—liver—colon cancer	0.000891	0.0132	CbGeAlD
Tacrolimus—CYP3A7-CYP3A51P—liver—colon cancer	0.000843	0.0125	CbGeAlD
Tacrolimus—FKBP1A—liver—colon cancer	0.000801	0.0119	CbGeAlD
Tacrolimus—ORM1—bone marrow—colon cancer	0.000776	0.0115	CbGeAlD
Tacrolimus—Temsirolimus—ABCB1—colon cancer	0.000727	0.532	CrCbGaD
Tacrolimus—MTOR—lymph node—colon cancer	0.000683	0.0101	CbGeAlD
Tacrolimus—ABCB1—blood vessel—colon cancer	0.000672	0.00995	CbGeAlD
Tacrolimus—Sirolimus—ABCB1—colon cancer	0.00064	0.468	CrCbGaD
Tacrolimus—ORM1—liver—colon cancer	0.000627	0.00929	CbGeAlD
Tacrolimus—FKBP1A—lymph node—colon cancer	0.000614	0.0091	CbGeAlD
Tacrolimus—CYP3A5—renal system—colon cancer	0.000571	0.00846	CbGeAlD
Tacrolimus—ALB—liver—colon cancer	0.00055	0.00815	CbGeAlD
Tacrolimus—ORM1—lymph node—colon cancer	0.000481	0.00713	CbGeAlD
Tacrolimus—CYP3A5—digestive system—colon cancer	0.000468	0.00694	CbGeAlD
Tacrolimus—CYP3A4—renal system—colon cancer	0.000429	0.00635	CbGeAlD
Tacrolimus—ALB—lymph node—colon cancer	0.000422	0.00625	CbGeAlD
Tacrolimus—CYP3A5—vagina—colon cancer	0.000414	0.00613	CbGeAlD
Tacrolimus—ABCB1—embryo—colon cancer	0.000401	0.00594	CbGeAlD
Tacrolimus—CYP3A4—digestive system—colon cancer	0.000351	0.00521	CbGeAlD
Tacrolimus—CYP3A5—liver—colon cancer	0.000349	0.00517	CbGeAlD
Tacrolimus—ABCB1—epithelium—colon cancer	0.000327	0.00484	CbGeAlD
Tacrolimus—ABCB1—renal system—colon cancer	0.000303	0.00449	CbGeAlD
Tacrolimus—CYP3A4—liver—colon cancer	0.000262	0.00388	CbGeAlD
Tacrolimus—ABCB1—lymphoid tissue—colon cancer	0.000252	0.00373	CbGeAlD
Tacrolimus—ABCB1—digestive system—colon cancer	0.000249	0.00369	CbGeAlD
Tacrolimus—ABCB1—bone marrow—colon cancer	0.000229	0.0034	CbGeAlD
Tacrolimus—ABCB1—vagina—colon cancer	0.00022	0.00325	CbGeAlD
Tacrolimus—ABCB1—liver—colon cancer	0.000185	0.00275	CbGeAlD
Tacrolimus—ABCB1—lymph node—colon cancer	0.000142	0.00211	CbGeAlD
Tacrolimus—Hypotension—Vincristine—colon cancer	0.000126	0.000694	CcSEcCtD
Tacrolimus—Bradycardia—Capecitabine—colon cancer	0.000126	0.000693	CcSEcCtD
Tacrolimus—Anaphylactic shock—Fluorouracil—colon cancer	0.000125	0.000692	CcSEcCtD
Tacrolimus—Oedema—Fluorouracil—colon cancer	0.000125	0.000692	CcSEcCtD
Tacrolimus—Anorexia—Irinotecan—colon cancer	0.000125	0.000689	CcSEcCtD
Tacrolimus—Infection—Fluorouracil—colon cancer	0.000125	0.000688	CcSEcCtD
Tacrolimus—Haemoglobin—Capecitabine—colon cancer	0.000124	0.000684	CcSEcCtD
Tacrolimus—Rhinitis—Capecitabine—colon cancer	0.000124	0.000683	CcSEcCtD
Tacrolimus—Haemorrhage—Capecitabine—colon cancer	0.000123	0.000681	CcSEcCtD
Tacrolimus—Hepatitis—Capecitabine—colon cancer	0.000123	0.000681	CcSEcCtD
Tacrolimus—Nervous system disorder—Fluorouracil—colon cancer	0.000123	0.000679	CcSEcCtD
Tacrolimus—Thrombocytopenia—Fluorouracil—colon cancer	0.000123	0.000678	CcSEcCtD
Tacrolimus—Hypoaesthesia—Capecitabine—colon cancer	0.000123	0.000678	CcSEcCtD
Tacrolimus—Liver function test abnormal—Methotrexate—colon cancer	0.000122	0.000677	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Vincristine—colon cancer	0.000122	0.000676	CcSEcCtD
Tacrolimus—Pharyngitis—Capecitabine—colon cancer	0.000122	0.000676	CcSEcCtD
Tacrolimus—Tachycardia—Fluorouracil—colon cancer	0.000122	0.000676	CcSEcCtD
Tacrolimus—Hypotension—Irinotecan—colon cancer	0.000122	0.000675	CcSEcCtD
Tacrolimus—Urinary tract disorder—Capecitabine—colon cancer	0.000122	0.000673	CcSEcCtD
Tacrolimus—Insomnia—Vincristine—colon cancer	0.000122	0.000671	CcSEcCtD
Tacrolimus—Oedema peripheral—Capecitabine—colon cancer	0.000121	0.000671	CcSEcCtD
Tacrolimus—Connective tissue disorder—Capecitabine—colon cancer	0.000121	0.000669	CcSEcCtD
Tacrolimus—Urethral disorder—Capecitabine—colon cancer	0.000121	0.000668	CcSEcCtD
Tacrolimus—Paraesthesia—Vincristine—colon cancer	0.000121	0.000667	CcSEcCtD
Tacrolimus—Breast disorder—Methotrexate—colon cancer	0.00012	0.000662	CcSEcCtD
Tacrolimus—Anorexia—Fluorouracil—colon cancer	0.000119	0.00066	CcSEcCtD
Tacrolimus—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.000119	0.00066	CcSEcCtD
Tacrolimus—Visual impairment—Capecitabine—colon cancer	0.000119	0.000656	CcSEcCtD
Tacrolimus—Insomnia—Irinotecan—colon cancer	0.000118	0.000654	CcSEcCtD
Tacrolimus—Paraesthesia—Irinotecan—colon cancer	0.000118	0.000649	CcSEcCtD
Tacrolimus—Hypotension—Fluorouracil—colon cancer	0.000117	0.000647	CcSEcCtD
Tacrolimus—Decreased appetite—Vincristine—colon cancer	0.000117	0.000645	CcSEcCtD
Tacrolimus—Dyspnoea—Irinotecan—colon cancer	0.000117	0.000644	CcSEcCtD
Tacrolimus—Erythema multiforme—Capecitabine—colon cancer	0.000117	0.000644	CcSEcCtD
Tacrolimus—Somnolence—Irinotecan—colon cancer	0.000116	0.000643	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Vincristine—colon cancer	0.000116	0.000641	CcSEcCtD
Tacrolimus—Fatigue—Vincristine—colon cancer	0.000116	0.00064	CcSEcCtD
Tacrolimus—Eye disorder—Capecitabine—colon cancer	0.000115	0.000636	CcSEcCtD
Tacrolimus—Dyspepsia—Irinotecan—colon cancer	0.000115	0.000636	CcSEcCtD
Tacrolimus—Tinnitus—Capecitabine—colon cancer	0.000115	0.000635	CcSEcCtD
Tacrolimus—Pain—Vincristine—colon cancer	0.000115	0.000635	CcSEcCtD
Tacrolimus—Constipation—Vincristine—colon cancer	0.000115	0.000635	CcSEcCtD
Tacrolimus—Asthma—Methotrexate—colon cancer	0.000115	0.000633	CcSEcCtD
Tacrolimus—Cardiac disorder—Capecitabine—colon cancer	0.000114	0.000632	CcSEcCtD
Tacrolimus—Flushing—Capecitabine—colon cancer	0.000114	0.000632	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000114	0.000631	CcSEcCtD
Tacrolimus—Decreased appetite—Irinotecan—colon cancer	0.000114	0.000628	CcSEcCtD
Tacrolimus—Insomnia—Fluorouracil—colon cancer	0.000113	0.000626	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Irinotecan—colon cancer	0.000113	0.000624	CcSEcCtD
Tacrolimus—Fatigue—Irinotecan—colon cancer	0.000113	0.000623	CcSEcCtD
Tacrolimus—Paraesthesia—Fluorouracil—colon cancer	0.000113	0.000622	CcSEcCtD
Tacrolimus—Pancreatitis—Methotrexate—colon cancer	0.000112	0.000621	CcSEcCtD
Tacrolimus—Constipation—Irinotecan—colon cancer	0.000112	0.000618	CcSEcCtD
Tacrolimus—Pain—Irinotecan—colon cancer	0.000112	0.000618	CcSEcCtD
Tacrolimus—Angiopathy—Capecitabine—colon cancer	0.000112	0.000618	CcSEcCtD
Tacrolimus—Dyspnoea—Fluorouracil—colon cancer	0.000112	0.000617	CcSEcCtD
Tacrolimus—Somnolence—Fluorouracil—colon cancer	0.000111	0.000615	CcSEcCtD
Tacrolimus—Immune system disorder—Capecitabine—colon cancer	0.000111	0.000615	CcSEcCtD
Tacrolimus—Mediastinal disorder—Capecitabine—colon cancer	0.000111	0.000614	CcSEcCtD
Tacrolimus—Chills—Capecitabine—colon cancer	0.000111	0.000611	CcSEcCtD
Tacrolimus—Dyspepsia—Fluorouracil—colon cancer	0.00011	0.000609	CcSEcCtD
Tacrolimus—Arrhythmia—Capecitabine—colon cancer	0.00011	0.000608	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Vincristine—colon cancer	0.00011	0.000607	CcSEcCtD
Tacrolimus—Decreased appetite—Fluorouracil—colon cancer	0.000109	0.000602	CcSEcCtD
Tacrolimus—Alopecia—Capecitabine—colon cancer	0.000109	0.000602	CcSEcCtD
Tacrolimus—Pancytopenia—Methotrexate—colon cancer	0.000109	0.000601	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000108	0.000598	CcSEcCtD
Tacrolimus—Mental disorder—Capecitabine—colon cancer	0.000108	0.000597	CcSEcCtD
Tacrolimus—Feeling abnormal—Irinotecan—colon cancer	0.000108	0.000596	CcSEcCtD
Tacrolimus—Erythema—Capecitabine—colon cancer	0.000107	0.000593	CcSEcCtD
Tacrolimus—Malnutrition—Capecitabine—colon cancer	0.000107	0.000593	CcSEcCtD
Tacrolimus—Neutropenia—Methotrexate—colon cancer	0.000107	0.000592	CcSEcCtD
Tacrolimus—Dysuria—Methotrexate—colon cancer	0.000107	0.000592	CcSEcCtD
Tacrolimus—Pain—Fluorouracil—colon cancer	0.000107	0.000592	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Irinotecan—colon cancer	0.000107	0.000591	CcSEcCtD
Tacrolimus—Abdominal pain—Vincristine—colon cancer	0.000106	0.000587	CcSEcCtD
Tacrolimus—Body temperature increased—Vincristine—colon cancer	0.000106	0.000587	CcSEcCtD
Tacrolimus—Flatulence—Capecitabine—colon cancer	0.000106	0.000584	CcSEcCtD
Tacrolimus—Dysgeusia—Capecitabine—colon cancer	0.000105	0.000581	CcSEcCtD
Tacrolimus—Photosensitivity reaction—Methotrexate—colon cancer	0.000105	0.000578	CcSEcCtD
Tacrolimus—Back pain—Capecitabine—colon cancer	0.000104	0.000573	CcSEcCtD
Tacrolimus—Body temperature increased—Irinotecan—colon cancer	0.000103	0.000571	CcSEcCtD
Tacrolimus—Abdominal pain—Irinotecan—colon cancer	0.000103	0.000571	CcSEcCtD
Tacrolimus—Feeling abnormal—Fluorouracil—colon cancer	0.000103	0.000571	CcSEcCtD
Tacrolimus—Muscle spasms—Capecitabine—colon cancer	0.000103	0.00057	CcSEcCtD
Tacrolimus—Pneumonia—Methotrexate—colon cancer	0.000103	0.000568	CcSEcCtD
Tacrolimus—Infestation NOS—Methotrexate—colon cancer	0.000102	0.000565	CcSEcCtD
Tacrolimus—Infestation—Methotrexate—colon cancer	0.000102	0.000565	CcSEcCtD
Tacrolimus—Depression—Methotrexate—colon cancer	0.000102	0.000563	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000101	0.00056	CcSEcCtD
Tacrolimus—Vision blurred—Capecitabine—colon cancer	0.000101	0.000559	CcSEcCtD
Tacrolimus—Tremor—Capecitabine—colon cancer	0.000101	0.000555	CcSEcCtD
Tacrolimus—Renal failure—Methotrexate—colon cancer	0.000101	0.000555	CcSEcCtD
Tacrolimus—Stomatitis—Methotrexate—colon cancer	9.97e-05	0.00055	CcSEcCtD
Tacrolimus—Ill-defined disorder—Capecitabine—colon cancer	9.96e-05	0.00055	CcSEcCtD
Tacrolimus—Urticaria—Fluorouracil—colon cancer	9.96e-05	0.00055	CcSEcCtD
Tacrolimus—Conjunctivitis—Methotrexate—colon cancer	9.94e-05	0.000549	CcSEcCtD
Tacrolimus—Anaemia—Capecitabine—colon cancer	9.92e-05	0.000548	CcSEcCtD
Tacrolimus—Body temperature increased—Fluorouracil—colon cancer	9.91e-05	0.000547	CcSEcCtD
Tacrolimus—Hypersensitivity—Vincristine—colon cancer	9.9e-05	0.000547	CcSEcCtD
Tacrolimus—Sweating—Methotrexate—colon cancer	9.8e-05	0.000541	CcSEcCtD
Tacrolimus—Haematuria—Methotrexate—colon cancer	9.75e-05	0.000538	CcSEcCtD
Tacrolimus—Malaise—Capecitabine—colon cancer	9.68e-05	0.000535	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Methotrexate—colon cancer	9.67e-05	0.000534	CcSEcCtD
Tacrolimus—Epistaxis—Methotrexate—colon cancer	9.64e-05	0.000533	CcSEcCtD
Tacrolimus—Vertigo—Capecitabine—colon cancer	9.64e-05	0.000533	CcSEcCtD
Tacrolimus—Hypersensitivity—Irinotecan—colon cancer	9.64e-05	0.000533	CcSEcCtD
Tacrolimus—Asthenia—Vincristine—colon cancer	9.64e-05	0.000533	CcSEcCtD
Tacrolimus—Syncope—Capecitabine—colon cancer	9.63e-05	0.000532	CcSEcCtD
Tacrolimus—Leukopenia—Capecitabine—colon cancer	9.61e-05	0.000531	CcSEcCtD
Tacrolimus—Agranulocytosis—Methotrexate—colon cancer	9.54e-05	0.000527	CcSEcCtD
Tacrolimus—Palpitations—Capecitabine—colon cancer	9.48e-05	0.000524	CcSEcCtD
Tacrolimus—Loss of consciousness—Capecitabine—colon cancer	9.43e-05	0.000521	CcSEcCtD
Tacrolimus—Asthenia—Irinotecan—colon cancer	9.39e-05	0.000519	CcSEcCtD
Tacrolimus—Cough—Capecitabine—colon cancer	9.37e-05	0.000517	CcSEcCtD
Tacrolimus—Hypertension—Capecitabine—colon cancer	9.27e-05	0.000512	CcSEcCtD
Tacrolimus—Hypersensitivity—Fluorouracil—colon cancer	9.24e-05	0.00051	CcSEcCtD
Tacrolimus—Haemoglobin—Methotrexate—colon cancer	9.22e-05	0.00051	CcSEcCtD
Tacrolimus—Diarrhoea—Vincristine—colon cancer	9.2e-05	0.000508	CcSEcCtD
Tacrolimus—Hepatitis—Methotrexate—colon cancer	9.18e-05	0.000507	CcSEcCtD
Tacrolimus—Haemorrhage—Methotrexate—colon cancer	9.18e-05	0.000507	CcSEcCtD
Tacrolimus—Chest pain—Capecitabine—colon cancer	9.14e-05	0.000505	CcSEcCtD
Tacrolimus—Myalgia—Capecitabine—colon cancer	9.14e-05	0.000505	CcSEcCtD
Tacrolimus—Arthralgia—Capecitabine—colon cancer	9.14e-05	0.000505	CcSEcCtD
Tacrolimus—Pharyngitis—Methotrexate—colon cancer	9.11e-05	0.000503	CcSEcCtD
Tacrolimus—Anxiety—Capecitabine—colon cancer	9.11e-05	0.000503	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	9.07e-05	0.000501	CcSEcCtD
Tacrolimus—Urinary tract disorder—Methotrexate—colon cancer	9.06e-05	0.000501	CcSEcCtD
Tacrolimus—Discomfort—Capecitabine—colon cancer	9.03e-05	0.000499	CcSEcCtD
Tacrolimus—Urethral disorder—Methotrexate—colon cancer	9e-05	0.000497	CcSEcCtD
Tacrolimus—Diarrhoea—Irinotecan—colon cancer	8.95e-05	0.000495	CcSEcCtD
Tacrolimus—Dry mouth—Capecitabine—colon cancer	8.94e-05	0.000494	CcSEcCtD
Tacrolimus—Dizziness—Vincristine—colon cancer	8.89e-05	0.000491	CcSEcCtD
Tacrolimus—Pruritus—Fluorouracil—colon cancer	8.87e-05	0.00049	CcSEcCtD
Tacrolimus—Visual impairment—Methotrexate—colon cancer	8.85e-05	0.000489	CcSEcCtD
Tacrolimus—Confusional state—Capecitabine—colon cancer	8.83e-05	0.000488	CcSEcCtD
Tacrolimus—Oedema—Capecitabine—colon cancer	8.76e-05	0.000484	CcSEcCtD
Tacrolimus—Infection—Capecitabine—colon cancer	8.7e-05	0.000481	CcSEcCtD
Tacrolimus—Erythema multiforme—Methotrexate—colon cancer	8.68e-05	0.000479	CcSEcCtD
Tacrolimus—Dizziness—Irinotecan—colon cancer	8.65e-05	0.000478	CcSEcCtD
Tacrolimus—Shock—Capecitabine—colon cancer	8.62e-05	0.000476	CcSEcCtD
Tacrolimus—Nervous system disorder—Capecitabine—colon cancer	8.59e-05	0.000474	CcSEcCtD
Tacrolimus—Eye disorder—Methotrexate—colon cancer	8.58e-05	0.000474	CcSEcCtD
Tacrolimus—Diarrhoea—Fluorouracil—colon cancer	8.58e-05	0.000474	CcSEcCtD
Tacrolimus—Thrombocytopenia—Capecitabine—colon cancer	8.58e-05	0.000474	CcSEcCtD
Tacrolimus—Tinnitus—Methotrexate—colon cancer	8.56e-05	0.000473	CcSEcCtD
Tacrolimus—Tachycardia—Capecitabine—colon cancer	8.55e-05	0.000472	CcSEcCtD
Tacrolimus—Vomiting—Vincristine—colon cancer	8.54e-05	0.000472	CcSEcCtD
Tacrolimus—Cardiac disorder—Methotrexate—colon cancer	8.52e-05	0.00047	CcSEcCtD
Tacrolimus—Skin disorder—Capecitabine—colon cancer	8.51e-05	0.00047	CcSEcCtD
Tacrolimus—Rash—Vincristine—colon cancer	8.47e-05	0.000468	CcSEcCtD
Tacrolimus—Hyperhidrosis—Capecitabine—colon cancer	8.47e-05	0.000468	CcSEcCtD
Tacrolimus—Dermatitis—Vincristine—colon cancer	8.47e-05	0.000468	CcSEcCtD
Tacrolimus—Headache—Vincristine—colon cancer	8.42e-05	0.000465	CcSEcCtD
Tacrolimus—Anorexia—Capecitabine—colon cancer	8.35e-05	0.000461	CcSEcCtD
Tacrolimus—Angiopathy—Methotrexate—colon cancer	8.33e-05	0.00046	CcSEcCtD
Tacrolimus—Vomiting—Irinotecan—colon cancer	8.32e-05	0.00046	CcSEcCtD
Tacrolimus—Immune system disorder—Methotrexate—colon cancer	8.29e-05	0.000458	CcSEcCtD
Tacrolimus—Dizziness—Fluorouracil—colon cancer	8.29e-05	0.000458	CcSEcCtD
Tacrolimus—Mediastinal disorder—Methotrexate—colon cancer	8.27e-05	0.000457	CcSEcCtD
Tacrolimus—Rash—Irinotecan—colon cancer	8.25e-05	0.000456	CcSEcCtD
Tacrolimus—Dermatitis—Irinotecan—colon cancer	8.24e-05	0.000455	CcSEcCtD
Tacrolimus—Chills—Methotrexate—colon cancer	8.24e-05	0.000455	CcSEcCtD
Tacrolimus—Headache—Irinotecan—colon cancer	8.2e-05	0.000453	CcSEcCtD
Tacrolimus—Hypotension—Capecitabine—colon cancer	8.19e-05	0.000452	CcSEcCtD
Tacrolimus—Alopecia—Methotrexate—colon cancer	8.11e-05	0.000448	CcSEcCtD
Tacrolimus—Mental disorder—Methotrexate—colon cancer	8.04e-05	0.000444	CcSEcCtD
Tacrolimus—Erythema—Methotrexate—colon cancer	7.99e-05	0.000441	CcSEcCtD
Tacrolimus—Malnutrition—Methotrexate—colon cancer	7.99e-05	0.000441	CcSEcCtD
Tacrolimus—Nausea—Vincristine—colon cancer	7.98e-05	0.000441	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Capecitabine—colon cancer	7.98e-05	0.000441	CcSEcCtD
Tacrolimus—Vomiting—Fluorouracil—colon cancer	7.97e-05	0.00044	CcSEcCtD
Tacrolimus—Insomnia—Capecitabine—colon cancer	7.92e-05	0.000438	CcSEcCtD
Tacrolimus—Rash—Fluorouracil—colon cancer	7.9e-05	0.000437	CcSEcCtD
Tacrolimus—Dermatitis—Fluorouracil—colon cancer	7.9e-05	0.000436	CcSEcCtD
Tacrolimus—Paraesthesia—Capecitabine—colon cancer	7.87e-05	0.000434	CcSEcCtD
Tacrolimus—Headache—Fluorouracil—colon cancer	7.85e-05	0.000434	CcSEcCtD
Tacrolimus—Dysgeusia—Methotrexate—colon cancer	7.82e-05	0.000432	CcSEcCtD
Tacrolimus—Dyspnoea—Capecitabine—colon cancer	7.81e-05	0.000431	CcSEcCtD
Tacrolimus—Nausea—Irinotecan—colon cancer	7.77e-05	0.000429	CcSEcCtD
Tacrolimus—Back pain—Methotrexate—colon cancer	7.73e-05	0.000427	CcSEcCtD
Tacrolimus—Dyspepsia—Capecitabine—colon cancer	7.71e-05	0.000426	CcSEcCtD
Tacrolimus—Decreased appetite—Capecitabine—colon cancer	7.61e-05	0.000421	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Capecitabine—colon cancer	7.56e-05	0.000418	CcSEcCtD
Tacrolimus—Fatigue—Capecitabine—colon cancer	7.55e-05	0.000417	CcSEcCtD
Tacrolimus—Vision blurred—Methotrexate—colon cancer	7.53e-05	0.000416	CcSEcCtD
Tacrolimus—Pain—Capecitabine—colon cancer	7.49e-05	0.000414	CcSEcCtD
Tacrolimus—Constipation—Capecitabine—colon cancer	7.49e-05	0.000414	CcSEcCtD
Tacrolimus—Nausea—Fluorouracil—colon cancer	7.45e-05	0.000411	CcSEcCtD
Tacrolimus—Ill-defined disorder—Methotrexate—colon cancer	7.41e-05	0.000409	CcSEcCtD
Tacrolimus—Anaemia—Methotrexate—colon cancer	7.38e-05	0.000408	CcSEcCtD
Tacrolimus—Feeling abnormal—Capecitabine—colon cancer	7.22e-05	0.000399	CcSEcCtD
Tacrolimus—Malaise—Methotrexate—colon cancer	7.21e-05	0.000398	CcSEcCtD
Tacrolimus—Vertigo—Methotrexate—colon cancer	7.18e-05	0.000396	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Capecitabine—colon cancer	7.16e-05	0.000396	CcSEcCtD
Tacrolimus—Leukopenia—Methotrexate—colon cancer	7.15e-05	0.000395	CcSEcCtD
Tacrolimus—Cough—Methotrexate—colon cancer	6.97e-05	0.000385	CcSEcCtD
Tacrolimus—Urticaria—Capecitabine—colon cancer	6.96e-05	0.000384	CcSEcCtD
Tacrolimus—Body temperature increased—Capecitabine—colon cancer	6.92e-05	0.000382	CcSEcCtD
Tacrolimus—Abdominal pain—Capecitabine—colon cancer	6.92e-05	0.000382	CcSEcCtD
Tacrolimus—Convulsion—Methotrexate—colon cancer	6.92e-05	0.000382	CcSEcCtD
Tacrolimus—Chest pain—Methotrexate—colon cancer	6.8e-05	0.000376	CcSEcCtD
Tacrolimus—Arthralgia—Methotrexate—colon cancer	6.8e-05	0.000376	CcSEcCtD
Tacrolimus—Myalgia—Methotrexate—colon cancer	6.8e-05	0.000376	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	6.76e-05	0.000373	CcSEcCtD
Tacrolimus—Discomfort—Methotrexate—colon cancer	6.72e-05	0.000371	CcSEcCtD
Tacrolimus—Confusional state—Methotrexate—colon cancer	6.58e-05	0.000363	CcSEcCtD
Tacrolimus—Anaphylactic shock—Methotrexate—colon cancer	6.52e-05	0.00036	CcSEcCtD
Tacrolimus—Infection—Methotrexate—colon cancer	6.48e-05	0.000358	CcSEcCtD
Tacrolimus—Hypersensitivity—Capecitabine—colon cancer	6.45e-05	0.000356	CcSEcCtD
Tacrolimus—Nervous system disorder—Methotrexate—colon cancer	6.39e-05	0.000353	CcSEcCtD
Tacrolimus—Thrombocytopenia—Methotrexate—colon cancer	6.38e-05	0.000353	CcSEcCtD
Tacrolimus—Skin disorder—Methotrexate—colon cancer	6.33e-05	0.00035	CcSEcCtD
Tacrolimus—Hyperhidrosis—Methotrexate—colon cancer	6.3e-05	0.000348	CcSEcCtD
Tacrolimus—Asthenia—Capecitabine—colon cancer	6.28e-05	0.000347	CcSEcCtD
Tacrolimus—Anorexia—Methotrexate—colon cancer	6.22e-05	0.000343	CcSEcCtD
Tacrolimus—Pruritus—Capecitabine—colon cancer	6.2e-05	0.000342	CcSEcCtD
Tacrolimus—Hypotension—Methotrexate—colon cancer	6.09e-05	0.000337	CcSEcCtD
Tacrolimus—Diarrhoea—Capecitabine—colon cancer	5.99e-05	0.000331	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Methotrexate—colon cancer	5.94e-05	0.000328	CcSEcCtD
Tacrolimus—Insomnia—Methotrexate—colon cancer	5.9e-05	0.000326	CcSEcCtD
Tacrolimus—Paraesthesia—Methotrexate—colon cancer	5.86e-05	0.000323	CcSEcCtD
Tacrolimus—Dyspnoea—Methotrexate—colon cancer	5.81e-05	0.000321	CcSEcCtD
Tacrolimus—Somnolence—Methotrexate—colon cancer	5.8e-05	0.00032	CcSEcCtD
Tacrolimus—Dizziness—Capecitabine—colon cancer	5.79e-05	0.00032	CcSEcCtD
Tacrolimus—Dyspepsia—Methotrexate—colon cancer	5.74e-05	0.000317	CcSEcCtD
Tacrolimus—Decreased appetite—Methotrexate—colon cancer	5.67e-05	0.000313	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Methotrexate—colon cancer	5.63e-05	0.000311	CcSEcCtD
Tacrolimus—Fatigue—Methotrexate—colon cancer	5.62e-05	0.000311	CcSEcCtD
Tacrolimus—Pain—Methotrexate—colon cancer	5.58e-05	0.000308	CcSEcCtD
Tacrolimus—Vomiting—Capecitabine—colon cancer	5.57e-05	0.000308	CcSEcCtD
Tacrolimus—Rash—Capecitabine—colon cancer	5.52e-05	0.000305	CcSEcCtD
Tacrolimus—Dermatitis—Capecitabine—colon cancer	5.52e-05	0.000305	CcSEcCtD
Tacrolimus—Headache—Capecitabine—colon cancer	5.49e-05	0.000303	CcSEcCtD
Tacrolimus—Feeling abnormal—Methotrexate—colon cancer	5.37e-05	0.000297	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Methotrexate—colon cancer	5.33e-05	0.000295	CcSEcCtD
Tacrolimus—Nausea—Capecitabine—colon cancer	5.2e-05	0.000287	CcSEcCtD
Tacrolimus—Urticaria—Methotrexate—colon cancer	5.18e-05	0.000286	CcSEcCtD
Tacrolimus—Abdominal pain—Methotrexate—colon cancer	5.15e-05	0.000285	CcSEcCtD
Tacrolimus—Body temperature increased—Methotrexate—colon cancer	5.15e-05	0.000285	CcSEcCtD
Tacrolimus—Hypersensitivity—Methotrexate—colon cancer	4.8e-05	0.000265	CcSEcCtD
Tacrolimus—Asthenia—Methotrexate—colon cancer	4.68e-05	0.000258	CcSEcCtD
Tacrolimus—Pruritus—Methotrexate—colon cancer	4.61e-05	0.000255	CcSEcCtD
Tacrolimus—Diarrhoea—Methotrexate—colon cancer	4.46e-05	0.000246	CcSEcCtD
Tacrolimus—Dizziness—Methotrexate—colon cancer	4.31e-05	0.000238	CcSEcCtD
Tacrolimus—Vomiting—Methotrexate—colon cancer	4.15e-05	0.000229	CcSEcCtD
Tacrolimus—Rash—Methotrexate—colon cancer	4.11e-05	0.000227	CcSEcCtD
Tacrolimus—Dermatitis—Methotrexate—colon cancer	4.11e-05	0.000227	CcSEcCtD
Tacrolimus—Headache—Methotrexate—colon cancer	4.09e-05	0.000226	CcSEcCtD
Tacrolimus—Nausea—Methotrexate—colon cancer	3.87e-05	0.000214	CcSEcCtD
Tacrolimus—MTOR—Signaling by ERBB2—AKT1—colon cancer	3.81e-05	0.000404	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—FGFR3—colon cancer	3.8e-05	0.000403	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—AKT1—colon cancer	3.79e-05	0.000402	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—APC—colon cancer	3.78e-05	0.000402	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—FGFR3—colon cancer	3.78e-05	0.000401	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—NRAS—colon cancer	3.76e-05	0.000399	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CA7—colon cancer	3.76e-05	0.000399	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—HRAS—colon cancer	3.74e-05	0.000397	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—colon cancer	3.73e-05	0.000396	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CHST5—colon cancer	3.69e-05	0.000392	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ODC1—colon cancer	3.69e-05	0.000392	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—HRAS—colon cancer	3.6e-05	0.000382	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—colon cancer	3.58e-05	0.00038	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—AKT1—colon cancer	3.57e-05	0.000378	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—AKT1—colon cancer	3.57e-05	0.000378	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—colon cancer	3.57e-05	0.000378	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—AKT1—colon cancer	3.53e-05	0.000375	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—AKT1—colon cancer	3.5e-05	0.000372	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—AKT1—colon cancer	3.49e-05	0.00037	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—APC—colon cancer	3.47e-05	0.000368	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—EGFR—colon cancer	3.43e-05	0.000364	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—FGFR3—colon cancer	3.41e-05	0.000362	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—PTGS2—colon cancer	3.4e-05	0.000361	CbGpPWpGaD
Tacrolimus—ABCB1—HIF-1-alpha transcription factor network—AKT1—colon cancer	3.38e-05	0.000359	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—AKT1—colon cancer	3.3e-05	0.00035	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CTNNB1—colon cancer	3.29e-05	0.00035	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—BRAF—colon cancer	3.26e-05	0.000346	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—KRAS—colon cancer	3.24e-05	0.000343	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CDKN1A—colon cancer	3.22e-05	0.000341	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CDH1—colon cancer	3.21e-05	0.00034	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—AKT1—colon cancer	3.18e-05	0.000337	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—colon cancer	3.16e-05	0.000335	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—APC—colon cancer	3.13e-05	0.000333	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—NRAS—colon cancer	3.13e-05	0.000333	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—TP53—colon cancer	3.07e-05	0.000325	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—EP300—colon cancer	3.06e-05	0.000325	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—CTNNB1—colon cancer	3.04e-05	0.000323	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—SRC—colon cancer	2.98e-05	0.000316	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—PIK3CA—colon cancer	2.97e-05	0.000316	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—CDKN1A—colon cancer	2.97e-05	0.000315	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—BRAF—colon cancer	2.95e-05	0.000313	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	2.87e-05	0.000305	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—NRAS—colon cancer	2.86e-05	0.000304	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—EGFR—colon cancer	2.86e-05	0.000303	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—EP300—colon cancer	2.83e-05	0.0003	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD8A—colon cancer	2.82e-05	0.000299	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—HRAS—colon cancer	2.75e-05	0.000292	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—SRC—colon cancer	2.75e-05	0.000292	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—KRAS—colon cancer	2.7e-05	0.000286	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	2.67e-05	0.000283	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—FGFR3—colon cancer	2.65e-05	0.000281	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—NRAS—colon cancer	2.64e-05	0.000281	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PTGS2—colon cancer	2.64e-05	0.00028	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—EGFR—colon cancer	2.61e-05	0.000277	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	2.6e-05	0.000276	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	2.57e-05	0.000273	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	2.51e-05	0.000267	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—PIK3CA—colon cancer	2.48e-05	0.000263	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CTNNB1—colon cancer	2.47e-05	0.000262	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—KRAS—colon cancer	2.46e-05	0.000262	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—MYC—colon cancer	2.46e-05	0.000261	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—TGFB1—colon cancer	2.46e-05	0.000261	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—APC—colon cancer	2.43e-05	0.000258	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—AKT1—colon cancer	2.43e-05	0.000258	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—EGFR—colon cancer	2.41e-05	0.000256	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CDKN1A—colon cancer	2.41e-05	0.000256	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—BCL2L1—colon cancer	2.41e-05	0.000256	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	2.39e-05	0.000254	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—ABCB1—colon cancer	2.38e-05	0.000252	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—SRC—colon cancer	2.36e-05	0.00025	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—CTNNB1—colon cancer	2.36e-05	0.00025	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	2.32e-05	0.000247	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CDKN1A—colon cancer	2.31e-05	0.000246	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—CDKN1A—colon cancer	2.3e-05	0.000244	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—FGFR3—colon cancer	2.3e-05	0.000244	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—VEGFA—colon cancer	2.3e-05	0.000244	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—HRAS—colon cancer	2.29e-05	0.000243	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—EP300—colon cancer	2.29e-05	0.000243	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—BRAF—colon cancer	2.28e-05	0.000242	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CHST5—colon cancer	2.28e-05	0.000242	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ODC1—colon cancer	2.28e-05	0.000242	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—KRAS—colon cancer	2.28e-05	0.000242	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—PIK3CA—colon cancer	2.26e-05	0.00024	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	2.26e-05	0.00024	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—SRC—colon cancer	2.23e-05	0.000237	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CASP3—colon cancer	2.21e-05	0.000234	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—EP300—colon cancer	2.19e-05	0.000233	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CCND1—colon cancer	2.15e-05	0.000228	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—NRAS—colon cancer	2.14e-05	0.000228	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—SRC—colon cancer	2.14e-05	0.000227	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—SRC—colon cancer	2.13e-05	0.000226	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CTNNB1—colon cancer	2.13e-05	0.000226	CbGpPWpGaD
Tacrolimus—MTOR—Disease—FGFR3—colon cancer	2.13e-05	0.000226	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—TGFB1—colon cancer	2.11e-05	0.000224	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HRAS—colon cancer	2.1e-05	0.000222	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—PIK3CA—colon cancer	2.09e-05	0.000222	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	2.08e-05	0.000221	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CDKN1A—colon cancer	2.08e-05	0.000221	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	2.08e-05	0.00022	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—NRAS—colon cancer	2.06e-05	0.000219	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—NRAS—colon cancer	2.05e-05	0.000218	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	2.04e-05	0.000216	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—AKT1—colon cancer	2.02e-05	0.000215	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—EP300—colon cancer	1.98e-05	0.00021	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—EGFR—colon cancer	1.95e-05	0.000207	CbGpPWpGaD
Tacrolimus—MTOR—Disease—APC—colon cancer	1.95e-05	0.000207	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CDH1—colon cancer	1.95e-05	0.000207	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—HRAS—colon cancer	1.93e-05	0.000205	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—SRC—colon cancer	1.92e-05	0.000204	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	1.92e-05	0.000204	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—MYC—colon cancer	1.91e-05	0.000203	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—TGFB1—colon cancer	1.91e-05	0.000202	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—EGFR—colon cancer	1.88e-05	0.000199	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—VEGFA—colon cancer	1.87e-05	0.000199	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—EGFR—colon cancer	1.87e-05	0.000198	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—NRAS—colon cancer	1.85e-05	0.000197	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—AKT1—colon cancer	1.85e-05	0.000196	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—KRAS—colon cancer	1.85e-05	0.000196	CbGpPWpGaD
Tacrolimus—MTOR—Disease—BRAF—colon cancer	1.83e-05	0.000195	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	1.8e-05	0.000191	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—ABCB1—colon cancer	1.79e-05	0.00019	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—KRAS—colon cancer	1.77e-05	0.000188	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	1.77e-05	0.000188	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—KRAS—colon cancer	1.76e-05	0.000187	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—TYMS—colon cancer	1.76e-05	0.000187	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.74e-05	0.000185	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MYC—colon cancer	1.72e-05	0.000183	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TGFB1—colon cancer	1.72e-05	0.000183	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CASP3—colon cancer	1.71e-05	0.000182	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	1.71e-05	0.000181	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—AKT1—colon cancer	1.71e-05	0.000181	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—PIK3CA—colon cancer	1.7e-05	0.00018	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—EGFR—colon cancer	1.69e-05	0.000179	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CCND1—colon cancer	1.67e-05	0.000177	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CTNNB1—colon cancer	1.65e-05	0.000175	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—PIK3CA—colon cancer	1.63e-05	0.000173	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PIK3CA—colon cancer	1.62e-05	0.000172	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CDKN1A—colon cancer	1.61e-05	0.000171	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—KRAS—colon cancer	1.59e-05	0.000169	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—HRAS—colon cancer	1.57e-05	0.000166	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—EP300—colon cancer	1.53e-05	0.000163	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HRAS—colon cancer	1.51e-05	0.00016	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—HRAS—colon cancer	1.5e-05	0.000159	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—SRC—colon cancer	1.49e-05	0.000158	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—FGFR3—colon cancer	1.49e-05	0.000158	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTGS2—colon cancer	1.48e-05	0.000157	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—AKT1—colon cancer	1.47e-05	0.000156	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PIK3CA—colon cancer	1.46e-05	0.000155	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—VEGFA—colon cancer	1.45e-05	0.000154	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	1.44e-05	0.000153	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CTNNB1—colon cancer	1.44e-05	0.000152	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—NRAS—colon cancer	1.44e-05	0.000152	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TP53—colon cancer	1.42e-05	0.00015	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CDKN1A—colon cancer	1.4e-05	0.000149	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—AKT1—colon cancer	1.39e-05	0.000147	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.37e-05	0.000145	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—APC—colon cancer	1.37e-05	0.000145	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—HRAS—colon cancer	1.35e-05	0.000144	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MYC—colon cancer	1.34e-05	0.000142	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—EP300—colon cancer	1.34e-05	0.000142	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TGFB1—colon cancer	1.33e-05	0.000142	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—AKT1—colon cancer	1.33e-05	0.000141	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CTNNB1—colon cancer	1.33e-05	0.000141	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—AKT1—colon cancer	1.32e-05	0.000141	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—EGFR—colon cancer	1.31e-05	0.000139	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—SRC—colon cancer	1.3e-05	0.000138	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CDKN1A—colon cancer	1.3e-05	0.000137	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ABCB1—colon cancer	1.29e-05	0.000137	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—BRAF—colon cancer	1.28e-05	0.000136	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—TYMS—colon cancer	1.27e-05	0.000135	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—EP300—colon cancer	1.25e-05	0.000133	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—NRAS—colon cancer	1.25e-05	0.000133	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PPARG—colon cancer	1.25e-05	0.000132	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—KRAS—colon cancer	1.24e-05	0.000131	CbGpPWpGaD
Tacrolimus—MTOR—Disease—EP300—colon cancer	1.23e-05	0.000131	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—SRC—colon cancer	1.22e-05	0.000129	CbGpPWpGaD
Tacrolimus—MTOR—Disease—SRC—colon cancer	1.2e-05	0.000127	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—AKT1—colon cancer	1.2e-05	0.000127	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—VEGFA—colon cancer	1.18e-05	0.000126	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—NRAS—colon cancer	1.17e-05	0.000124	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NRAS—colon cancer	1.15e-05	0.000122	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.14e-05	0.000121	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—EGFR—colon cancer	1.14e-05	0.000121	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PIK3CA—colon cancer	1.14e-05	0.00012	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ABCB1—colon cancer	1.11e-05	0.000118	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TP53—colon cancer	1.1e-05	0.000117	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—TYMS—colon cancer	1.09e-05	0.000116	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TGFB1—colon cancer	1.09e-05	0.000115	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—KRAS—colon cancer	1.07e-05	0.000114	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MYC—colon cancer	1.07e-05	0.000114	CbGpPWpGaD
Tacrolimus—MTOR—Disease—TGFB1—colon cancer	1.07e-05	0.000114	CbGpPWpGaD
Tacrolimus—MTOR—Disease—EGFR—colon cancer	1.05e-05	0.000111	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—HRAS—colon cancer	1.05e-05	0.000111	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—KRAS—colon cancer	1.01e-05	0.000107	CbGpPWpGaD
Tacrolimus—MTOR—Disease—KRAS—colon cancer	9.92e-06	0.000105	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PIK3CA—colon cancer	9.88e-06	0.000105	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTGS2—colon cancer	9.8e-06	0.000104	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CASP3—colon cancer	9.63e-06	0.000102	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—TYMS—colon cancer	9.59e-06	0.000102	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCND1—colon cancer	9.38e-06	9.95e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CTNNB1—colon cancer	9.29e-06	9.86e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—AKT1—colon cancer	9.27e-06	9.84e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PIK3CA—colon cancer	9.25e-06	9.82e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HRAS—colon cancer	9.14e-06	9.7e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PIK3CA—colon cancer	9.12e-06	9.68e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CDKN1A—colon cancer	9.07e-06	9.63e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PPARG—colon cancer	9e-06	9.55e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TP53—colon cancer	8.95e-06	9.5e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EP300—colon cancer	8.63e-06	9.16e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—HRAS—colon cancer	8.56e-06	9.09e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—HRAS—colon cancer	8.44e-06	8.95e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	8.42e-06	8.94e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SRC—colon cancer	8.39e-06	8.91e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—VEGFA—colon cancer	8.18e-06	8.68e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—EP300—colon cancer	8.15e-06	8.65e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NRAS—colon cancer	8.07e-06	8.57e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—AKT1—colon cancer	8.07e-06	8.56e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PPARG—colon cancer	7.75e-06	8.23e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—AKT1—colon cancer	7.56e-06	8.02e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MYC—colon cancer	7.52e-06	7.98e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TGFB1—colon cancer	7.5e-06	7.96e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—AKT1—colon cancer	7.45e-06	7.91e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EGFR—colon cancer	7.36e-06	7.81e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTGS2—colon cancer	7.08e-06	7.52e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KRAS—colon cancer	6.95e-06	7.38e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PPARG—colon cancer	6.79e-06	7.21e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CA—colon cancer	6.39e-06	6.78e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TP53—colon cancer	6.18e-06	6.56e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTGS2—colon cancer	6.1e-06	6.47e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CA—colon cancer	6.03e-06	6.4e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ABCB1—colon cancer	6.02e-06	6.38e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—TYMS—colon cancer	5.91e-06	6.27e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HRAS—colon cancer	5.91e-06	6.27e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—EP300—colon cancer	5.89e-06	6.25e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTGS2—colon cancer	5.34e-06	5.67e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AKT1—colon cancer	5.22e-06	5.54e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—EP300—colon cancer	5.07e-06	5.38e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—AKT1—colon cancer	4.92e-06	5.23e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—EP300—colon cancer	4.44e-06	4.72e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CA—colon cancer	4.36e-06	4.62e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PPARG—colon cancer	4.18e-06	4.44e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CA—colon cancer	3.75e-06	3.98e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—AKT1—colon cancer	3.56e-06	3.78e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTGS2—colon cancer	3.29e-06	3.49e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CA—colon cancer	3.29e-06	3.49e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AKT1—colon cancer	3.07e-06	3.25e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—EP300—colon cancer	2.74e-06	2.91e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AKT1—colon cancer	2.69e-06	2.85e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CA—colon cancer	2.03e-06	2.15e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AKT1—colon cancer	1.65e-06	1.76e-05	CbGpPWpGaD
